"All study participants who got severe dengue, whether vaccinated or not, have fully recovered", Sanofi Pasteur General Manager Ching Santos said in a media briefing.
While Sanofiâ Dengvaxia is the first-ever approved vaccine for dengue, scientists already recognised it was not perfect and did not protect equally against the four different types of the virus in clinical tests.
Health officials called on parents to follow the usual dengue prevention measures, including destroying possible breeding places of mosquitoes, seeking early consultation for fever lasting more than two days, and using mosquito nets and mosquito fogging.
The DoH has suspended the program after manufacturer French pharmaceutical giant Sanofi Pasteur warned that it could worsen the disease in some cases.
The Philippines has launched an investigation into the immunisation of 730,000 children with a dengue vaccine that could pose health risks.
The Philippine government says there were more than 1,000 deaths caused by the disease last year, out of around 211,000 suspected cases. However, the Department of Health (DOH) stopped its implementation after Sanofi released its recent analysis.
CVS Health Corp's proposed purchase of Aetna Inc will change the way many major U.S. corporations buy health coverage for employees and raise new questions over the cost of those benefits, benefit consultants said.
Meanwhile, Sanofi Pasteur medical director Dr. Ruby Dizon stressed that a person's exposure to the dengue virus causes the disease and not the Dengvaxia vaccine itself.
"We see fewer hospitalisation and fewer cases of severe dengue among those who were vaccinated against those who received a placebo", she said.
The individual mandate is meant to ensure a viable health insurance market by forcing younger and healthier Americans to buy coverage to help offset the cost of sicker patients.
"In addition, the producer has to meet seven conditions before the product can be brought into Malaysia".
But, the vaccine does the opposite of what it's supposed to do, and actually increases the risk of contracting more severe dengue for those who have never been infected before.
"We need a database to identify the 70,000 affected children and know where they are exactly located in order for the government to keep track of their health and prepare the needed resources and logistics that will allow for quick and appropriate medical responses, if needed".
Since the dengue immunization was carried out in April 2016, 733,713 children from Central Luzon, the region of Cavite, Laguna, Batangas, Rizal, and Quezon, and Metro Manila were administered Dengvaxia.